Member Info for Blessed22

@emprex

What's your agenda?
You are posting the adverse effect of INJECTED interferon beta.
Synairgen's formulation is INHALED.
So your random post don't make any sense at all.
Do some research and don't post crap.

In my opinion the MAP agreement has been made in order to have the drug available within Europe, in anticipation of a UK approval.
So that after the company will be in a stronger position to negotiate with big pharmas and eventually take the drug to market.
By half October onwards all this will be clearer.

And keep certain that the company is doing the best they can to expedite the process.

Patience

ATB

Can't post it

Uk stock market for all is called.

************************************************

Antonios

************************************************?ref=share

Join
No nonsense

RM said 1 million doses by year end not 100k pm in 2021.

1 mllion by year end

The MAP is affordable to the company. The term “Managed Access Program” encompasses a variety of regulatory mechanisms globally, with the primary objective of providing treatment to patients prior to marketing approval. The mechanisms include Expanded Access Program (EAP), Named Patient Program (NPP), Autorisations Temporaires d’Utilisation (ATU) nominative (individual) or cohort (group) programs, and Compassionate Use Program (CUP).

MAPs can be implemented on a patient-by-patient basis, or, in some countries, for a group of patients. MAPs address the “access gap” that exists at any time during a drug’s lifecycle when patient demand exceeds patient access for a drug. The greater the unmet medical need, the larger the access gap.

When a company establishes a MAP, it is usually for one of the following objectives:

To make a drug in clinical development available to patients who are unable to participate in a clinical trial

To make a treatment available to study participants after the completion of a study, but before it becomes commercially available

To make an approved drug available to patients with a different therapeutic indication or in a different population

To make a treatment that has been approved in one country available in a country where it has not yet been approved or where approval is not expected.

To make a treatment available when commercialization is unlikely even though the drug benefits a small population with, for example, a rare disease

To make a drug available after development or commercialization in a specific market has been terminated but current patients still need treatment

That's the right directions.

Respecfully, you are wrong.

It might open with 5% gap up from 165p, which is the opening price, and trade from there.
If for instance closes at 170 it will be a +5p from the previous close, today.

It shouldn't take much longer for us PIs to know where we stand.
Government should start to speak up, peer review should be on the table by now and emergency approval of SNG001 expedited, given the current situation.
I am expecting an exciting month ahead with positive news on all fronts.
We have waited long enough.

THE TIME has come for SYNAIRGEN to be HEARD!!

It will open at 165p whcih is the closing price. Unless there are major news.
Aim manipulation is beyond limits.

By the sound of this board I presume there are a few.
Hope you get a margin call Tomorrow from your broker.
You ll then probably disappear from here forever.

Vaccines are treatments are both on the table.
Governments will not overlook treatments.

A pandemic is something unprecedented I dont think that if a treatment is proven to be working, safe to be used with other medication and significantly effective against the visus it can be overlooked from any government or pharma company.
Any treatment could save lifes helping to restablish a prospective normality, boost economies and bring this to an end.
Vaccines they always have more publicity but there is still a long way to go before any of them can be proven to be 100% safe, for all the age groups, and made available globally.

Treatments and vaccines are both needed urgently.
There will be more than a vaccine and there won't be a single treatment.

Big pharmas are profit orientated, where there is to make money, especially in the world we are living at present they will make war between each in order to have an effective treatment in their hand.
And in order to defeat covid we ll need both.

Either way it cannot be priced imo.
As someone said earlier the SP could be ten times higher than it is now in a matter of months.

Our last big news were out in July, two months have gone.

SNG is close to something unprecedented, same as us mere PIs.

Peer review/ approval and then will be only a waiting game.

Awaiting for these RNSs....
Gla

My target exit point remains always at a market cap of 4/5 billions.

Gla

Synairgen (SNG) could generate order books worth multiples of its market capitalisation for its SNG001 drug, house broker FinnCap has argued, after positive results from a trial of its Covid-19 treatment.

Shares in Synairgen soared 421% to 190p yesterday after a phase two trial of its coronavirus treatment, which reported a 79% reduction in patients developing severe disease or death. Patients that were treated were also twice as likely to recover those on a placebo.

FinnCap analyst Mark Brewer, who rates the shares a ‘buy’ raised his price target from 120p to 360p on the news.

‘Valuing the Covid-19 opportunity is nigh on impossible; however, we upgrade our target price to 360p but recognise this could go substantially higher, based on upcoming discussions with regulators, which should clarify the route to market and the potential for buying SNG001 ahead of the winter 2020 flu season and the possibility of a second wave of Covid-19,’ he said.

Based on pricing points for [potential Covid-19 treatments] Rebif and Avonex and Gilead’s remdesivir ($2-3,000 per treatment), and the prospect of Synairgen being able to supply up to 1m doses by the end of 2020, it is not inconceivable that an order book of $2-3bn could be generated by the year-end, which would imply a valuation substantially higher than 360p (circa £0.5bn market cap).’

Source: Citywire

Just a reminder.

Yesterday's medical update on excately where we are with treatments and vaccines.

Interferon Beta Inhaled is mentioned.

"In mid-July, scientists in the United Kingdom reported success in initial tests with a protein called interferon beta. The protein is produced by the body during viral infections.

The researchers said the protein is inhaled directly into the lungs of someone infected with the novel coronavirus in hopes of stimulating an immune response.

They said the protein reduced the odds of developing a severe form of the disease in hospitalized patients by 79 percent."

https://www.healthline.com/health-news/heres-exactly-where-were-at-with-vaccines-and-treatments-for-covid-19#Searching-for-effective-treatments

B

Forgot the link

https://www.google.co.uk/amp/s/www.rollingstone.com/politics/politics-features/big-pharma-covid-19-profits-1041185/amp/

Interesting article about covid 19 vaccines and treatments potential value.

"This was the case with Sovaldi, for instance, which Gilead acquired when it spent $11 billion in 2012 buying out original developer Pharmasset, which had worked on a line of hepatitis drugs. Within five years, Gilead earned more than $58 billion on a line of hepatitis treatments it won in the Pharmasset deal."

Very interesting overall. Also clarifying and comparing Phases I II III in countries outside the US against FDA approvals for marketing new drugs.

TENS OF MILLIONS is what you ll come across.
People on here have been talking about 10/20£ per share.
It could be VERY WELL POSSIBLE!

ATB

Eva I strongly think you are full of sh*t.

Filtered

How does a stock move from otc to a major exchange?

"The company and its stock must meet listing requirements for its price per share, total value, corporate profits, daily or monthly trading volume, revenues, and SEC reporting requirements. For example, the NYSE requires newly listed companies to have 1.1 million publicly held shares held by a minimum of 2,200 shareholders with a collective market value of at least $100 million. Companies that want to list on the Nasdaq, on the other hand, are required to have 1.25 million public shares held by at least 550 shareholders with a collective market value of $45 million."

https://www.investopedia.com/ask/answers/08/otc-nyse-nasdaq.asp

Macosta
Go and have a walk in the park it's sunny outside.

I will remember your post when our shares go up to 800p.

Muppet